Literature DB >> 32363116

The prognostic role of NK cells and their ligands in squamous cell carcinoma of the head and neck: a systematic review and meta-analysis.

Sangeeta K Bisheshar1, Emma J De Ruiter1, Lot A Devriese2, Stefan M Willems1.   

Abstract

Background : Despite the improvement in therapeutic interventions, 5-year survival rates in Head and Neck Squamous Cell Carcinoma (HNSCC) are limited. HNSCC is an immunogenic cancer type for which molecular stratification markers are lacking. Tumor-infiltrating lymphocytes (TILs) have shown a favorable prognostic role in different cancer types. This study focused on the prognostic role of NK cells in HNSCC. Methods : A systematic search was conducted in Pubmed/Medline and Embase. Articles that correlated the presence of intratumoral NK cells, activating/inhibiting receptors, death receptors, or their ligands with clinicopathologic characteristics or survival were included. A meta-analysis was performed that assessed the association between CD56+ and CD57+ and overall survival (OS), disease-free survival (DFS), and progression-free survival (PFS). Results : A pooled analysis indicated a favorable prognostic role of CD56+ and CD57+ NK cells for OS (HR 0.19 CI 0.11-0.35). NK cell markers NKp46 and Granzyme B (GrB) also have a favorable prognostic role. NK cell ligand Fas correlated with better survival and better characteristics. NK cell marker Fas-L, NK cell ligands CEACAM1, RCAS1, CD70 and TRAIL-R, and effector molecules of these ligands, FADD and FAP1, correlated to features of worse prognosis. Conclusion : A favorable prognostic role of NK cells in HNSCC was found in this review. Some studies implied the opposite, indicating the fine balance between pro- and anti-tumor functions of NK cells. Future studies using homogeneous patient cohorts regarding tumor subsite and treatment modality, are necessary to further provide insight into the prognostic role of NK cells.
© 2020 The Author(s). Published with license by Taylor & Francis Group, LLC.

Entities:  

Keywords:  Head and neck squamous cell carcinoma (HNSCC); prognostic biomarkers; systematic review; NK cell markers; NK cells

Mesh:

Substances:

Year:  2020        PMID: 32363116      PMCID: PMC7185215          DOI: 10.1080/2162402X.2020.1747345

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


  94 in total

1.  Immunogenomic correlates of response to cetuximab monotherapy in head and neck squamous cell carcinoma.

Authors:  Daniel L Faden; Fernando Concha-Benavente; Anish B Chakka; Elizabeth L McMichael; Uma Chandran; Robert L Ferris
Journal:  Head Neck       Date:  2019-03-04       Impact factor: 3.147

2.  Prognostic implication of CD57, CD16, and TGF-β expression in oral squamous cell carcinoma.

Authors:  Nasim Taghavi; Sara Bagheri; Alireza Akbarzadeh
Journal:  J Oral Pathol Med       Date:  2015-03-24       Impact factor: 4.253

3.  The clinicopathological significance of the expression of Granzyme B in oral squamous cell carcinoma.

Authors:  Nádia Lago Costa; Rita de Cássia Gonçalves Alencar; Marize Campos Valadares; Tarcília Aparecida Silva; Elismauro Francisco Mendonça; Aline Carvalho Batista
Journal:  Oral Oncol       Date:  2010-01-08       Impact factor: 5.337

4.  Natural killer cell-based therapies.

Authors:  François Romagné; Eric Vivier
Journal:  F1000 Med Rep       Date:  2011-05-03

Review 5.  Trailing TRAIL Resistance: Novel Targets for TRAIL Sensitization in Cancer Cells.

Authors:  Rachana Trivedi; Durga Prasad Mishra
Journal:  Front Oncol       Date:  2015-04-02       Impact factor: 6.244

Review 6.  The prognostic role of tumor infiltrating T-lymphocytes in squamous cell carcinoma of the head and neck: A systematic review and meta-analysis.

Authors:  Emma J de Ruiter; Marc L Ooft; Lot A Devriese; Stefan M Willems
Journal:  Oncoimmunology       Date:  2017-08-09       Impact factor: 8.110

Review 7.  CD56 in the Immune System: More Than a Marker for Cytotoxicity?

Authors:  Heleen H Van Acker; Anna Capsomidis; Evelien L Smits; Viggo F Van Tendeloo
Journal:  Front Immunol       Date:  2017-07-24       Impact factor: 7.561

Review 8.  The promise of immunotherapy in head and neck squamous cell carcinoma: combinatorial immunotherapy approaches.

Authors:  Panagiota Economopoulou; Ioannis Kotsantis; Amanda Psyrri
Journal:  ESMO Open       Date:  2017-02-13

9.  Repression of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) but not its receptors during oral cancer progression.

Authors:  Nadarajah Vigneswaran; Darryl C Baucum; Jean Wu; Yahuan Lou; Jerry Bouquot; Susan Muller; Wolfgang Zacharias
Journal:  BMC Cancer       Date:  2007-06-25       Impact factor: 4.430

10.  FAS/FASL expression profile as a prognostic marker in squamous cell carcinoma of the oral cavity.

Authors:  Paulo Bentes de Carvalho-Neto; Marcelo dos Santos; Marcos Brasilino de Carvalho; Ana Maria da Cunha Mercante; Viviane Priscila Pina dos Santos; Patrícia Severino; Eloiza Helena Tajara; Iuri Drumond Louro; Adriana Madeira Álvares da Silva-Conforti
Journal:  PLoS One       Date:  2013-07-19       Impact factor: 3.240

View more
  14 in total

Review 1.  The 'Danse Macabre'-Neutrophils the Interactive Partner Affecting Oral Cancer Outcomes.

Authors:  Sara Hadjigol; Bansari A Shah; Neil M O'Brien-Simpson
Journal:  Front Immunol       Date:  2022-06-16       Impact factor: 8.786

Review 2.  Role of Adenoviruses in Cancer Therapy.

Authors:  Sintayehu Tsegaye Tseha
Journal:  Front Oncol       Date:  2022-06-09       Impact factor: 5.738

3.  Systemic Analysis on the Features of Immune Microenvironment Related to Prognostic Signature in Head and Neck Squamous Cell Carcinoma.

Authors:  Kaixin Su; Zekun Zhou; Qiao Yi; Junjie Liu; Tiao Luo; Xinyan Cui; Haixia Zhang
Journal:  Front Genet       Date:  2022-05-11       Impact factor: 4.772

4.  Identification of Prognostic Model Based on Immune-Related LncRNAs in Stage I-III Non-Small Cell Lung Cancer.

Authors:  Qiaxuan Li; Lintong Yao; Zenan Lin; Fasheng Li; Daipeng Xie; Congsen Li; Weijie Zhan; Weihuan Lin; Luyu Huang; Shaowei Wu; Haiyu Zhou
Journal:  Front Oncol       Date:  2021-10-20       Impact factor: 6.244

Review 5.  Postoperative Natural Killer Cell Dysfunction: The Prime Suspect in the Case of Metastasis Following Curative Cancer Surgery.

Authors:  Marisa Market; Gayashan Tennakoon; Rebecca C Auer
Journal:  Int J Mol Sci       Date:  2021-10-21       Impact factor: 5.923

6.  Assessment of Histological Features in Squamous Cell Carcinoma Involving Head and Neck Skin and Mucosa.

Authors:  Ana Caruntu; Liliana Moraru; Mihai Lupu; Diana Alina Ciubotaru; Marius Dumitrescu; Lucian Eftimie; Radu Hertzog; Sabina Zurac; Constantin Caruntu; Oana Cristina Voinea
Journal:  J Clin Med       Date:  2021-05-27       Impact factor: 4.241

7.  Prognostic Potential of Tumor-Infiltrating Immune Cells in Resectable Oral Squamous Cell Carcinoma.

Authors:  Ana Caruntu; Liliana Moraru; Mihai Lupu; Florina Vasilescu; Marius Dumitrescu; Mirela Cioplea; Cristiana Popp; Alexandra Dragusin; Constantin Caruntu; Sabina Zurac
Journal:  Cancers (Basel)       Date:  2021-05-08       Impact factor: 6.639

Review 8.  Immune deserts in head and neck squamous cell carcinoma: A review of challenges and opportunities for modulating the tumor immune microenvironment.

Authors:  Janice L Farlow; J Chad Brenner; Yu L Lei; Steven B Chinn
Journal:  Oral Oncol       Date:  2021-07-01       Impact factor: 5.972

9.  Assessment of Immune Cell Populations in Tumor Tissue and Peripheral Blood Samples from Head and Neck Squamous Cell Carcinoma Patients.

Authors:  Ana Caruntu; Liliana Moraru; Mihaela Surcel; Adriana Munteanu; Cristiana Tanase; Carolina Constantin; Sabina Zurac; Constantin Caruntu; Monica Neagu
Journal:  Anal Cell Pathol (Amst)       Date:  2021-10-15       Impact factor: 2.916

Review 10.  Tumor-Infiltrating Lymphocytes in Head and Neck Cancer: Ready for Prime Time?

Authors:  Alhadi Almangush; Stijn De Keukeleire; Sylvie Rottey; Liesbeth Ferdinande; Tijl Vermassen; Ilmo Leivo; Antti A Mäkitie
Journal:  Cancers (Basel)       Date:  2022-03-18       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.